Massage Envy adds second Walgreens executive to its team
SCOTTSDALE, Ariz. – Massage Envy Wednesday afternoon announced the appointment of former Walgreens veteran Beth Stiller as its new chief commercial officer. Stiller will be responsible for leading Massage Envy's services, retail, innovation and operations teams.
Stiller joins the company from Walgreens where she was the group VP global brands and sourcing.
"Beth and I have worked together in our previous roles and I'm excited to have her join the Massage Envy leadership team," stated Joe Magnacca, CEO Massage Envy. "Her proven ability to deliver on strategic initiatives, as well as her vast retail and franchise experience, will be a tremendous asset and complement to the team as we continue to innovate and drive business growth."
Stiller has more than 20 years of domestic and international experience in both franchise and corporate environments, with a proven track record in innovating the customer experience, developing product and services, along with strong operational skills. Previously Stiller spent six years at Walgreens/Duane Reade where she led product development, brand management and sourcing activities for a $4.7 billion multi-brand portfolio. She also repositioned five brands via a consumer-led and validated brand development exercise and delivered an integrated strategic plan to drive top line growth and enhanced brand equity.
"What a great opportunity to join such an incredible brand that has not only pioneered the convenient and affordable massage and skincare membership space but is now looking to innovate and transform the category once again," Stiller said. "I'm excited to join such a strong and experienced leadership team to help the brand and the franchise network on its next phase of continued growth."
Along with Magnacca, Stiller joins Massage Envy's leadership team comprised of Debbie Gonzalez, chief brand officer; George Hines, chief information officer; Melanie Hansen, general counsel; Lee Knowlton, SVP global franchise sales and international; and Greg Esgar, chief financial officer.
Massage Envy believes total body care is an integral part of everyone's well-being journey. Through its innovative membership model, the Massage Envy franchise system enables customers to utilize massage and skincare services as a regular part of their lives rather than as a luxury or only on special occasions. The Massage Envy franchise system has grown to more than 1,100 locations in the United States, and recently surpassed the milestone of delivering more than 100 million massages and facials to its members and guests.
FDA approves Jazz Pharmaceuticals’ Defitelio
SILVER SPRING, Md. — The Food and Drug Administration has approved Jazz Pharmaceuticals’ Defitelio (defibrotide sodium), a first-in-class treatment for a rare, life-threatening liver condition in patients who’ve received a stem cell transplant from blood or bone marrow.
Defitelio is indicated to treat hepatic veno-occlusive disease (VOD in patients with additional kidney or lung abnormalities that develops after a hematopoietic stem cell transplant (HCST). The condition causes some veins in the liver to be blocked, reducing blood flow in the liver. The most severe form of hepatic VOD can cause kidney and lung failure. Though only about 2% of HCST patients develop VOD, the mortality rate among those who do is 80%.
“The approval of Defitelio fills a significant need in the transplantation community to treat this rare but frequently fatal complication in patients who receive chemotherapy and HSCT,” said Dr. Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research.
The FDA granted priority review status to Defitelio and it received an orphan drug designation. The injectable drug’s distribution is expected to being within a week.
Omron names new president, CEO
LAKE FOREST, Ill. – Omron Healthcare on Thursday announced that Ranndy Kellogg has been named president and CEO. Kellogg assumes his new leadership position from his previous role of COO at Omron Healthcare. The executive transition, as approved by Omron Healthcare's board of directors and effective today, gives Kellogg responsibility for all operations in the U.S. and Canada, as well as administrative and operational support for Latin America.
Kellogg succeeds former managing executive officer, president and CEO Seiji Takeda, who will transition to the role of executive officer, global business strategy planning, sales and marketing, Europe and the Americas.
"In his 12 years at Omron Healthcare, Ranndy Kellogg has been a respected leader for our company and in the field of blood pressure monitors," Takeda said. "Mr. Kellogg's new position will provide him with greater latitude to spearhead Omron's continued growth and influence in the market. On behalf of the board of directors, I would like to thank Ranndy for his stewardship and contributions to Omron Healthcare's vision and growth for the past 11 years."
Prior to his work at Omron Healthcare, Kellogg served as VP and director of marketing for Baxter Healthcare. Before joining Baxter Healthcare, Kellogg held the position of group marketing manager at CR Bard. Kellogg holds a master's in business administration from Northwestern University's Kellogg School of Management.
"I am honored to have the opportunity to serve as CEO and president of Omron Healthcare and to lead our work forward to empower millions of people to take charge of their heart health through our most advanced, precise technology and tools on the market," Kellogg said.
"This year we are ramping up our mission to confront the ongoing epidemic of heart attacks and strokes – we will do that by building upon Omron's heritage of accuracy with new products that provide deeper insights, encourage behavioral change and promote healthier lifestyle habits."
Omron Healthcare's team of executives, led by Kellogg, hosted a first look at its "Project Zero" Wrist and Upper Arm Blood Pressure Monitors and the new OMRON Connect App at the Consumer Electronic Show in Las Vegas in January. These clinically-tested, highly accurate heart health tools – set to improve heart health for millions of hypertensive individuals – will be available this year and are part of a major heart health initiative that the company is rolling out in 2016.
Loading Post Please Wait...